Abstract
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).SARS-CoV-2 causes coronavirus disease, abbreviated as COVID-19.At the time of this writing, SARS-CoV-2 is spreading in multiple countries, threatening a pandemic that will affect billions of people.This virus appears to be a new human pathogen.Currently there are no vaccines, monoclonal antibodies (mAbs), or drugs available for SARS-CoV-2, although many are in rapid development and some may be available in a short time.This Viewpoint argues that human convalescent serum is an option for prevention and treatment of COVID-19 disease that could be rapidly available when there are sufficient numbers of people who have recovered and can donate immunoglobulin-containing serum.
Keywords
PandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakCoronavirusMonoclonal antibodyConvalescent plasmaImmunologyAntibodyMedicineVirusCoronaviridaeDiseaseBetacoronavirusInfectious disease (medical specialty)OutbreakInternal medicine
Affiliated Institutions
Related Publications
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
Significance Since SARS-CoV-2 emerged in China, it has spread rapidly around the world. Effective vaccines and therapeutics for SARS-CoV-2−induced disease (coronavirus disease 2...
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Abstract The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviru...
SARS-CoV-2 vaccines in development
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pande...
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Targeting the SARS-CoV-2 spike The surface of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is decorated with trimeric spikes that bind to host cell receptors. Th...
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome ...
Publication Info
- Year
- 2020
- Type
- article
- Volume
- 130
- Issue
- 4
- Pages
- 1545-1548
- Citations
- 978
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
978
OpenAlex
Cite This
Arturo Casadevall,
Liise‐anne Pirofski
(2020).
The convalescent sera option for containing COVID-19.
Journal of Clinical Investigation
, 130
(4)
, 1545-1548.
https://doi.org/10.1172/jci138003
Identifiers
- DOI
- 10.1172/jci138003